Neorecormon Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The neorecormon market research report is one of a series of new reports that provides neorecormon market statistics, including neorecormon industry global market size, regional shares, competitors with a neorecormon market share, detailed neorecormon market segments, market trends and opportunities, and any further data you may need to thrive in the neorecormon industry. This neorecormon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to expanding healthcare infrastructure in emerging markets, rising prevalence of chronic diseases, increasing demand for effective anemia treatments, government healthcare initiatives to support anemia management, and growth in cancer treatment leading to more chemotherapy-induced anemia cases. Major trends in the forecast period include a shift towards personalized medicine, the integration of digital health technologies in treatment management, the development of combination therapies for anemia, rising collaboration between pharmaceutical companies and healthcare providers, and advances in biosimilars and biologic therapies.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive the growth of the neorecormon market. CKD is a progressive condition where kidney function deteriorates over time, often leading to anemia due to reduced erythropoietin production. The growing number of CKD cases is fueled by factors such as an aging population and lifestyle-related diseases. Neorecormon plays a critical role in managing and improving the quality of life for individuals with CKD, particularly in addressing anemia, a common complication of the disease. According to a report from Kidney Research UK in June 2023, approximately 7.2 million people in the UK are living with CKD, which represents over 10% of the population. Of these, 3.25 million are in the advanced stages, while an additional 3.9 million are in the early stages. The number of people affected by CKD is expected to increase to 7.61 million by 2033. As a result, the growing prevalence of CKD is set to drive demand for neorecormon.

The rising healthcare expenditures are also expected to contribute to the growth of the neorecormon market. Healthcare expenditures encompass all spending on healthcare services, products, and activities within a specific time period, either at an individual, community, national, or global level. These expenditures are on the rise due to factors such as the increasing prevalence of chronic diseases, an aging population, advancements in medical technology, and growing demand for advanced healthcare services. Higher healthcare spending improves access to treatments such as neorecormon by expanding insurance coverage, reducing patient costs, and increasing funding for anemia management programs. This, in turn, facilitates early diagnosis and wider adoption of treatments, fostering market expansion, particularly in emerging economies. For example, in May 2023, the UK’s Office for National Statistics reported that healthcare expenditure in the UK had reached approximately $367 billion (£292 billion), marking an increase of 5.6%. Long-term health and social care expenditure also rose by 2.8% in 2022. Therefore, the ongoing rise in healthcare expenditures is poised to boost the neorecormon market.

The growing aging population is another key factor that is expected to drive the neorecormon market. As people age, their physiological functions gradually decline, making them more vulnerable to chronic conditions such as cancer and kidney diseases, both of which can lead to anemia. The aging population is expanding due to advances in healthcare, longer life expectancies, and declining birth rates. Neorecormon, as an erythropoiesis-stimulating agent (ESA), is vital in managing anemia by stimulating red blood cell production, improving energy levels, and enhancing overall treatment outcomes for elderly patients. According to Age UK, a charity for older people, there were 11 million people aged over 65 in England in 2023. This figure is expected to grow by 10% over the next five years and by 32% by 2043, adding 1.1 million and 3.5 million people, respectively. Thus, the expanding aging population is set to propel the neorecormon market.

The key company operating in the neorecormon market is F. Hoffmann-La Roche Ltd.

North America was the largest region in the neorecormon market in 2024. The regions covered in neorecormon report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neorecormon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Neorecormon is a biopharmaceutical used to treat anemia that arises from chronic kidney disease, chemotherapy, or other conditions that hinder red blood cell production. It functions as an erythropoietin-stimulating agent, which helps stimulate red blood cell production, thus enhancing oxygen circulation in the body.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Neorecormon is available in several formulations, with injectable solutions and pre-filled syringes being the most common. These injectable solutions are administered directly into the body using a needle or syringe. The injectable form of Neorecormon is primarily used to treat anemia in patients with chronic kidney disease (CKD), where it helps boost red blood cell production and improve oxygen delivery throughout the body. Its approved uses include treating anemia caused by CKD, cancer-related anemia, and anemia resulting from various other conditions. It is available for both adult and pediatric patients, distributed through channels such as hospitals, specialty clinics, retail pharmacies, and online pharmacies.

The neorecormon market consists of sales of erythropoietin-stimulating agents in formulations such as vials, cartridges, and ampoules. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.